BaylarJ. C., ByarD. P.: Expectant treatment of inoperable carcinoma of the prostate. Current controversies in urologic management, by Russel Scott, Jr., 95–98 (1972).
2.
BoltonB. H.: Pulmonary metastasis from carcinoma of prostate: incidence and case report of a long remission. J. Urol., 94; (1965).
3.
BoynsA. R., GolderM. P., DanutraV., HarperM. E., BrownseyB., ConleyT., JonesG. E., GriffithsK.: Prolactin studies mith the prostate prolactin and carcinogenesis, by A. R. Boyns & K. Griffiths, 207–215 (1972).
4.
BracciU., Di SilverioF.: Present procedure with regard to the use of hormone therapy in cases of cancer of the prostate. Excepta Medica, Amsterdam. Int. Congr., Series No. 290: 275 (1972).
5.
BracciU., Di SilverioF.: Il nostro attuale orientamento nella cura del cancro della prostata. Atti XVIII Settimana Medica Ospedali:89–93 (1973).
6.
BrendlerH.: Hormone therapy for inoperable carcinoma of the prostate. Current controversies in urologie management, by Russel Scott, Jr., 99–102 (1972).
7.
DodgeO. G., OworR., TempletonA. C.: Tumours of the male genitalia. Tumours in a tropical country, by A. C. Templeton: 133–144, Springer Verlag, New York1973.
8.
DollR. M., MuirC. S., WaterhouseJ.: Cancer incidence in five continents, Vol. II, U.I.C.C. Geneva, Springer Verlag1970.
9.
DunhamL. J., BailarJ. C.: World maps of cancer mortality rates and frequency ratios. J. Nat. Cancer Inst., 71; 155–204 (1968).
10.
FarnsworthW. E.: Prolactin and the prostate. Prolactin and carcinogenesis, by A. R. Boyns and K. Criffithes: 217–225 (1972).
11.
FlocksR. H.: Curative radiotherapy for carcinoma of the prostate. Current controversics in urologic management, by Russel Scott, Jr., 88–90 (1972).
12.
FranksL. M.: Etiology, epidemiology and pathology of prostate cancer. Cancer, 32; 1092–1095 (1973).
13.
GellerJ., FruchtmannB., NewmanH.: Effect of progestational agents on carcinoma of the prostate. Cancer Chemoter. Rep., 1; 41 (1967).
14.
GellerJ., VazakaG., FruchtmanB., NewmanH., NakaoK., LohA.: The effect of cyproterone acetate on advanced carcinoma of the prostate. Surg. Gynec. & Obst., 172; 748 (1968).
15.
HugginsC., RussellP. S.: Quantitative effects of hypophysectomy on testis and prostate of dogs. Endocrinology, 39; 1–7 (1946).
16.
JewettJ. H.: Radical perineal prostatectomy in the treatment of carcinoma of the prostate. Current controversies in urologie management, by Russell Scott, Jr., 81–84 (1972).
17.
LasnitxkiL.: The effect of prolactin on rat prostate glands in organ culture. Prolactin and carcinogenesis, by A. R. Boyns and K. Griffiths, 200–225 (1972).
18.
LattimerJ. K.: Radical retropubic prostatectomy in the treatment of carcinoma of the prostate. Current controversies in urologie management, by Russel Scott, Jr., 85–88 (1972).
19.
LawrenceA. M., LandauR. L.: (1965) From Boyns et al. (1972).
20.
MellingerG. T., CleasonD., BailarJ.: The histology and prognosis of prostatic cancer. J. Urol., 97 (1967).
21.
MurphyG. P.: Cancer of the prostate. Cancer, 32; 1089–1091 (1973).
22.
ProutG. R.: Diagnosis and staging of prostatic carcinoma. Cancer, 32; 1096–1102 (1973).
23.
SciarraF.: Testosterone and 4–androstenoids, concentration in peripheral and spermatic venous blood of patients with prostatic adenocarcinoma. Effects of diethylstilbestrol and cyproterone acetate therapy. J. Steroid. Bioch., 2; 313 (1971).
24.
ScottW. W.: Rationals and results of primary endocrine therapy in patients with prostatic cancer. Cancer, 32; 1119–1125 (1973).
25.
SmithR. B., WalshP. C., GodwinW. E.: Cyproterone acetate in the treatment of advanced carcinoma of the prostate. J. Urol., 110; 106–181 (1973).
26.
SorciniG., SciarraF., Di SilverioF.: Effect of cyproterone (SH 80881) and cyproterone acetate (SH 714) on plasma androgens in normal male. Folia Endocr., 82; 278 (1969).
27.
SorciniG.: Further studies on plasma androgens and gonadotropins after cyproterone acetate (SH 714). Folia Endocr., 24; 313 (1971).
28.
WhitmoreW. F.Jr.: The natural history of prostatic cancer. Cancer, 32; 1104–1132 (1973).
29.
WiynderE. L., MabuchiK., WhillmoreW. F.: Epidemiology of cancer of the prostate. Cancer, 28; 344–360 (1971).